Ara
Toplam kayıt 6, listelenen: 1-6
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
(Springer, 2021)
Purpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with ...
Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence
(Wiley, 2021)
A 34-year-old woman had a history of breast cancer and underwent a right-sided nipple-sparing mastectomy and axillary dissection in 2014. She was staged as pT2N2aM0, IIIA, and the histopathological type was TNBC, grade 3. ...
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer
(Taylor & Francis Ltd, 2022)
Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to ...
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
(Elsevier B.V., 2023)
Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ...
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
(Taylor and Francis Ltd., 2023)
To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ...
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
(Springer, 2024)
Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ...